Bio­mX’s phage ther­a­py suc­ceeds in Phase 2 di­a­bet­ic bone in­fec­tion study

Bio­mX’s an­tibac­te­r­i­al virus can­di­date has re­duced the size of foot ul­cers in pa­tients with di­a­bet­ic bone in­fec­tion en­rolled in a mid-stage tri­al. The find­ing could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER